{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:39:21Z","timestamp":1788406761805,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara Universitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["T\\u00DCB\\u0130TAK-2244"],"award-info":[{"award-number":["T\\u00DCB\\u0130TAK-2244"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["118C088"],"award-info":[{"award-number":["118C088"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jpba.2024.116039","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T11:34:45Z","timestamp":1707996885000},"page":"116039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A specific chiral HPLC method for lifitegrast and determination of enantiomeric impurity in drug substance, ophthalmic product and stressed samples"],"prefix":"10.1016","volume":"242","author":[{"given":"Merve","family":"U\u011fur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen","family":"Bellur Atici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel A.","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116039_bib1","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jpba.2024.116039_bib2","first-page":"1","article-title":"Lifitegrast: a novel drug for patients with dry eye disease","volume":"11","author":"Haber","year":"2019","journal-title":"Ther. Adv. Ophthalmol."},{"key":"10.1016\/j.jpba.2024.116039_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/OPTH.S5555","article-title":"Etiology, prevalence, and treatment of dry eye disease","volume":"3","author":"Gayton","year":"2009","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jpba.2024.116039_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40123-021-00373-y","article-title":"A narrative review of current understanding and classification of dry eye disease with new insights on the impact of dry eye during the COVID- 19 pandemic","volume":"10","author":"Barabino","year":"2021","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.jpba.2024.116039_bib5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/OPTH.S110557","article-title":"Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease","volume":"10","author":"Semba","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jpba.2024.116039_bib6","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1002\/slct.201904846","article-title":"An efficient and scalable synthesis of lifitegrast","volume":"5","author":"Rao Yerrabelly","year":"2020","journal-title":"ChemistrySelect"},{"issue":"1","key":"10.1016\/j.jpba.2024.116039_bib7","first-page":"1140","article-title":"A validated method developed for estimation of lifitegrast in bulk and pharmaceutical dosage form by UV-spectrophotometer and RP-HPLC","volume":"9","author":"Pannu","year":"2022","journal-title":"Austin J. Anal. Pharm. Chem."},{"key":"10.1016\/j.jpba.2024.116039_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123892","article-title":"Establishment of an LC-MS\/MS method for quantification of lifitegrast in rabbit plasma and ocular tissues and its application to pharmacokinetic study","volume":"1229","author":"Kim","year":"2023","journal-title":"J. Chromatogr. B"},{"issue":"11","key":"10.1016\/j.jpba.2024.116039_bib9","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1021\/acs.oprd.3c00228","article-title":"Development of a practical and scalable process for lifitegrast","volume":"27","author":"Madaraboina","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.jpba.2024.116039_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115845","article-title":"Investigation of aclidinium bromide degradation by stability-indicating HPLC methods, characterization of impurities by NMR, and identification of degradation products by LC-MS","volume":"238","author":"Yazar","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116039_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115636","article-title":"Insight into the photolytic degradation products of Rosuvastatin: Full chiral and structural elucidation and conversion kinetics by a combined chromatographic, spectroscopic and theoretical approach","volume":"236","author":"Borioni","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116039_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115239","article-title":"Chemo- and enantio-selective reversed-phase HPLC analysis of rosuvastatin using a cellulose-based chiral stationary phase in gradient elution mode","volume":"225","author":"Mammone","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116039_bib13","article-title":"Chiral LC method development: Stereo-selective separation, characterization, and determination of cabotegravir and related RS, RR, and SS isomeric impurities on coated cellulose-based chiral stationary phase by HILIC-LC and LC-MS","volume":"222","author":"Kasa","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116039_bib14","first-page":"1","article-title":"Separation and quantitative estimation of stereo-selective enantiomers of montelukast in pharmaceutical drug substance and tablets dosage forms by using stability-indicating normal phase-HPLC method","author":"Vadagam","year":"2023","journal-title":"Chirality"},{"key":"10.1016\/j.jpba.2024.116039_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113549","article-title":"Enantioselective separation of zopiclone on immobilized polysaccharide chiral stationary phase by HPLC: method development and validation","volume":"190","author":"Kozlov","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116039_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2023.464367","article-title":"Recent advances in chiral liquid chromatography stationary phases for pharmaceutical analysis","volume":"1708","author":"Liu","year":"2023","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jpba.2024.116039_bib17","series-title":"Second Ed","article-title":"Chiral Liquid Chromatography","author":"Wahab","year":"2018"},{"key":"10.1016\/j.jpba.2024.116039_bib18","series-title":"Specification of Drug Substances and Products, Development and Validation of Analytical Methods","first-page":"193","article-title":"Chiral methods","author":"He","year":"2013"},{"key":"10.1016\/j.jpba.2024.116039_bib19","unstructured":"ICH Guideline Q2 (R2), Step 5, Validation of analytical procedures, European Medicines Agency, EMA\/CHMP\/ICH\/82072\/2006, December 2023."},{"key":"10.1016\/j.jpba.2024.116039_bib20","unstructured":"ICH Guideline Q3A (R2), Step 5, Impurities in new drug substances, European Medicines Agency, CPMP\/ICH\/2737\/99, October 2006.."},{"key":"10.1016\/j.jpba.2024.116039_bib21","unstructured":"ICH Guideline Q3B (R2), Step 5, Impurities in new drug products, European Medicines Agency, CPMP\/ICH\/2738\/99, June 2006."},{"key":"10.1016\/j.jpba.2024.116039_bib22","unstructured":"I.C.H., Q6A Specifications: Test Procedures and Acceptance Criteria, European Medicines Agency, CPMP\/ICH\/2738\/99, May 2000."},{"key":"10.1016\/j.jpba.2024.116039_bib23","unstructured":"ICH Guideline Q1A (R2), Step 5, Stability testing of new drug substances and products validation of analytical procedures: Text and methodology, European Medicines Agency, CPMP\/ICH\/2736\/99, August 2003."},{"key":"10.1016\/j.jpba.2024.116039_bib24","unstructured":"ICH Guideline Q1B, Step 4, Stability testing: Photostability testing of new drug substances and products Q1B, International Conference on Harmonisation, November 1996."},{"key":"10.1016\/j.jpba.2024.116039_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.chroma.2018.07.033","article-title":"Hysteresis of retention and enantioselectivity on amylosetris (3,5-dimethylphenylcarbamate) chiral stationary phases in mixtures of 2-propanol and methanol","volume":"1568","author":"Horv\u00e1th","year":"2018","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jpba.2024.116039_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462741","article-title":"Chiral separation of oxazolidinone analogues by liquid chromatography on polysaccharide stationary phases using polar organic mode","volume":"1662","author":"Dob\u00f3","year":"2022","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.jpba.2024.116039_bib27","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.3390\/molecules28217419","article-title":"Molecular dynamics simulations of amylose- and cellulose-based selectors and related enantioseparations in liquid phase chromatography","volume":"28","author":"Dallocchio","year":"2023","journal-title":"Molecules"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:18:39Z","timestamp":1778512719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524000797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":27,"alternative-id":["S0731708524000797"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116039","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A specific chiral HPLC method for lifitegrast and determination of enantiomeric impurity in drug substance, ophthalmic product and stressed samples","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116039"}}